Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives
Clinical Microbiology Reviews · 13.06.2024 · 37 (2)
DOI: 10.1128/cmr.00152-22 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 13.06.2024. Verfasst von Sharana Mahomed. Beteiligte Einrichtung: Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, Univ…. Hauptthemen laut MEDLINE: HIV Infections, HIV Antibodies. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 336 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership (EDCTP), South African Medical Research Council (SAMRC).
Abstract (Originalsprache)
The human immunodeficiency virus (HIV) epidemic remains a formidable global health concern, with 39 million people living with the virus and 1.3 million new infections reported in 2022. Despite anti-retroviral therapy’s effectiveness in pre-exposure prophylaxis, its global adoption is limited. Broadly neutralizing antibodies (bNAbs) offer an alternative strategy for HIV prevention through passive immunization. Historically, passive immunization has been efficacious in the treatment of various diseases ranging from oncology to infectious diseases. Early clinical trials suggest bNAbs are safe, tolerable, and capable of reducing HIV RNA levels. Although challenges such as bNAb resistance have been noted in phase I trials, ongoing research aims to assess the additive or synergistic benefits of combining multiple bNAbs. Researchers are exploring bispecific and trispecific antibodies, and fragment crystallizable region modifications to augment antibody efficacy and half-life. Moreover, the potential of other antibody isotypes like IgG3 and IgA is under investigation. While promising, the application of bNAbs faces economic and logistical barriers. High manufacturing costs, particularly in resource-limited settings, and logistical challenges like cold-chain requirements pose obstacles. Preliminary studies suggest cost-effectiveness, although this is contingent on various factors like efficacy and distribution. Technological advancements and strategic partnerships may mitigate some challenges, but issues like molecular aggregation remain. The World Health Organization has provided preferred product characteristics for bNAbs, focusing on optimizing their efficacy, safety, and accessibility. The integration of bNAbs in HIV prophylaxis necessitates a multi-faceted approach, considering economic, logistical, and scientific variables. This review comprehensively covers the historical context, current advancements, and future avenues of bNAbs in HIV prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
ORCID-Profile: Sharana Mahomed
Förderung
- EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership (EDCTP)
- South African Medical Research Council (SAMRC)
Zitieren
APA
Mahomed, S. (2024). Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives. Clinical Microbiology Reviews, 37(2). https://doi.org/10.1128/cmr.00152-22
Vancouver
Mahomed S. Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives. Clinical Microbiology Reviews. 2024;37(2). doi:10.1128/cmr.00152-22
BibTeX
@article{Mahomed2024,
author = {Mahomed, Sharana},
title = {Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives},
journal = {Clinical Microbiology Reviews},
year = {2024},
volume = {37},
number = {2},
doi = {10.1128/cmr.00152-22}
}
EUVIMED